Home Cart Sign in  
Chemical Structure| 130018-87-0 Chemical Structure| 130018-87-0

Structure of Levocetirizine 2HCl
CAS No.: 130018-87-0

Chemical Structure| 130018-87-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Levocetirizine 2HCl is a third-generation non-sedative antihistamine, developed from the second-generation antihistamine cetirizine.

Synonyms: (R)-Cetirizine dihydrochloride; Xyzal; Xusal

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Levocetirizine 2HCl

CAS No. :130018-87-0
Formula : C21H27Cl3N2O3
M.W : 461.81
SMILES Code : O=C(O)COCCN1CCN([C@@H](C2=CC=C(Cl)C=C2)C3=CC=CC=C3)CC1.[H]Cl.[H]Cl
Synonyms :
(R)-Cetirizine dihydrochloride; Xyzal; Xusal
MDL No. :MFCD07366507
InChI Key :PGLIUCLTXOYQMV-GHVWMZMZSA-N
Pubchem ID :9955977

Safety of Levocetirizine 2HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of Levocetirizine 2HCl

GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Children Patients with allergic rhinitis Oral 5 mg Once every evening for 4 weeks To evaluate the safety and efficacy of levocetirizine and montelukast combination therapy in children with allergic rhinitis. Results showed that combination therapy was more effective than monotherapy in reducing both daytime and nighttime nasal symptoms. Allergy Asthma Immunol Res. 2024 Nov;16(6):652-667
Mice Parkinson's disease model Oral 0.5 and 1 mg/kg Once daily for 23 days To evaluate the effects of Levocetirizine on behavioral and biochemical parameters in a Parkinson's disease model in mice. Results showed that Levocetirizine significantly improved motor coordination, reduced catalepsy, and enhanced antioxidant enzyme activities. ACS Omega. 2022 Apr 20;7(17):14772-14783
Wistar rats Atopic dermatitis and MRSA skin infection model Topical administration 7.5 mg LVC 1 day Evaluate the deposition and safety of levocetirizine in the skin Pharmaceuticals (Basel). 2025 Apr 27;18(5):633
Male Wistar rats Alopecia model Topically 2.5 mg/mL Single dose, duration of 10 hours To evaluate the skin deposition of LVC from CCPCs, results showed that the AUC0-10 of the CCPCs group was significantly higher than that of the LVC solution group, indicating increased LVC deposition in the skin. Drug Deliv. 2022 Dec;29(1):2784-2795

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00521040 Rhinitis, Allergic, Seasonal COMPLETED 2025-07-04 -
NCT00521131 Rhinitis|Allergic|Perennial PHASE4 COMPLETED 2025-05-03 -
NCT00160680 Rhinitis, Allergic, Perennial PHASE4 COMPLETED 2006-06-01 Genova, Italy
NCT00521170 Allergy PHASE1 COMPLETED 2025-01-05 Illkirch, France|Strasbourg, F... More >>rance Less <<
NCT00315523 Rhinitis, Allergic, Seasonal PHASE3 COMPLETED 2025-10-06 Mississauga, Ontario, Canada
NCT00160537 Seasonal Allergic Rhinitis PHASE4 COMPLETED 2025-07-05 -
NCT00525278 Rhinitis|Allergic|Seasonal PHASE3 COMPLETED 2025-10-03 -
NCT00160589 Rhinitis, Allergic, Perennial PHASE4 COMPLETED 2025-09-05 -
NCT01445262 Rhinitis, Allergic, Perennial ... More >>and Seasonal Less << COMPLETED 2025-12-13 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.83mL

2.17mL

1.08mL

21.65mL

4.33mL

2.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories